MULTIPLE SCLEROSIS (MS) RELAPSING REMITTING
Clinical trials for MULTIPLE SCLEROSIS (MS) RELAPSING REMITTING explained in plain language.
Never miss a new study
Get alerted when new MULTIPLE SCLEROSIS (MS) RELAPSING REMITTING trials appear
Sign up with your email to follow new studies for MULTIPLE SCLEROSIS (MS) RELAPSING REMITTING, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Could a lighter MS treatment keep the disease at bay?
Disease control OngoingThis study tests whether people with relapsing-remitting multiple sclerosis (MS) who have been stable on anti-CD20 therapies can safely switch to a fumarate drug like Tecfidera or Vumerity. The goal is to see if the switch keeps the disease inactive—meaning no relapses, no new br…
Matched conditions: MULTIPLE SCLEROSIS (MS) RELAPSING REMITTING
Sponsor: University of Colorado, Denver • Aim: Disease control
Last updated Aug 13, 2026 00:00 UTC
-
Ear stimulation may help repair nerve damage in multiple sclerosis
Disease control ENROLLING_BY_INVITATIONThis study tests whether stimulating the vagus nerve through the ear, while doing a hand coordination task, can improve motor function in people with multiple sclerosis. Participants will receive either active or sham stimulation during 30-minute sessions over a month, with follo…
Matched conditions: MULTIPLE SCLEROSIS (MS) RELAPSING REMITTING
Phase: NA • Sponsor: University of Colorado, Denver • Aim: Disease control
Last updated Jul 08, 2026 00:00 UTC
-
MS trial withdrawn before it began: CAR T-Cell hope on hold
Disease control TerminatedThis study aimed to test a new treatment called CABA-201, a CAR T-cell therapy made from a patient's own immune cells, for people with multiple sclerosis (MS). The goal was to see if it was safe and could control the disease by targeting and resetting the immune system. However, …
Matched conditions: MULTIPLE SCLEROSIS (MS) RELAPSING REMITTING
Phase: PHASE1, PHASE2 • Sponsor: Cabaletta Bio • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
MS patients switch meds: will a cheaper option work just as well?
Disease control OngoingThis study looks at people with relapsing-remitting multiple sclerosis who switched from the drug MabThera to a similar, lower-cost medicine called Rixathon. Researchers want to see if the switch changes signs of nerve damage, new brain lesions, relapses, or disability. They will…
Matched conditions: MULTIPLE SCLEROSIS (MS) RELAPSING REMITTING
Sponsor: Uppsala University • Aim: Disease control
Last updated Jun 27, 2026 07:58 UTC
-
Healthy habits program aims to ease MS fatigue and boost Well-Being
Symptom relief OngoingThis study tests whether educational programs about exercise, Mediterranean diet, and mental strategies can improve quality of life and reduce fatigue in women with relapsing-remitting multiple sclerosis. About 60 participants will be assigned to either supervised in-person sessi…
Matched conditions: MULTIPLE SCLEROSIS (MS) RELAPSING REMITTING
Phase: NA • Sponsor: Universidad de Almeria • Aim: Symptom relief
Last updated Jun 27, 2026 12:00 UTC